المؤلفون: Yang Dong, Lai-Jun Deng, Mi-Mi Li

المصدر: World Journal of Clinical Cases

مصطلحات موضوعية: T-cell lymphoma/leukemia, Chemotherapy, business.industry, Mixed cellularity, medicine.medical_treatment, T-cell leukemia, General Medicine, Drug resistance, medicine.disease, Lymphoma, Leukemia, medicine.anatomical_structure, immune system diseases, hemic and lymphatic diseases, Case report, Cancer research, medicine, Bone marrow, business, Classical Hodgkin’s lymphoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2366a0fcacf7dc86944c03dcc3e95702Test
https://doi.org/10.12998/wjcc.v9.i27.8177Test

المصدر: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03907488Test

المؤلفون: National Cancer Institute (NCI)

المصدر: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03712202Test

المؤلفون: Merck Sharp & Dohme LLC, National Cancer Institute (NCI)

المساهمون: Jane N. Winter, Jane N. Winter, M.D.

المصدر: Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03077828Test

المصدر: A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00381940Test

المؤلفون: National Cancer Institute (NCI), Merck Sharp & Dohme LLC

المساهمون: Jane N. Winter, Principal Investigator

المصدر: Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03226249Test

المؤلفون: National Cancer Institute (NCI)

المصدر: A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00025259Test

المصدر: A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00082966Test

المصدر: A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00112723Test

المصدر: A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00132028Test